The FDA announced Friday that it had approved the first at-home test for sexually transmitted infections, opening the pathway for more to come.

The FDA has approved a new at-home test for common sexually transmitted infections and diseases. The test for chlamydia, ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...

Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity ...

The FDA on Friday granted marketing authorization to the first at-home test for diagnosing chlamydia, gonorrhea, and ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...

Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in ...

PARIS, France I March 26, 2025 I The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention ...

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety ...

Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 clinical study evaluating the immunogenicity and ...